US EditionTrump announces chips, drug probes, opening door to tariffs
- The Trump administration has commenced investigations into imports of pharmaceuticals and semiconductors, aiming to impose tariffs based on national security, as noted in notices published on the Federal Register.
- A public comment period of 21 days will follow the announcements regarding these sector investigations, according to the filings set for release on Wednesday.
- John Murphy III, CEO of the Association for Accessible Medicines, warned that tariffs could worsen drug shortages and reduce patient access, stating, 'Tariffs will only amplify the problems that already exist in the U.S. Market for affordable medicines.'
- President Donald Trump confirmed plans to apply tariffs on pharmaceuticals, declaring, 'We need to make our own drugs.
249 Articles
249 Articles
Tariffs: Why the threat of taxing semiconductors is "a dangerous game" for the global economy
Donald Trump has promised separate tariff measures on these essential components of the digital economy. At the risk of disrupting the supply chain and pushing US companies.
Trump Tariffs Roil Semiconductor Stocks, Test Loeb's Portfolio - Bloom Energy (NYSE:BE), Carpenter Tech (NYSE:CRS)
President Donald Trump established a new body within the Commerce Department to manage the CHIPS and Science Act of 2022, benefiting companies like Taiwan Semiconductor Manufacturing Co Ltd (NYSE:TSM). Here's a look at some of hedge fund manager Dan Loeb‘s semiconductor and electrical stocks year-to-date: NET Power Inc. (NYSE:NPWR) shares dropped 79.89%; its peer, Bloom Energy (NYSE:BE), saw a decline of 24.71% YTD. As of the fourth quarter of …
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Coverage Details
Bias Distribution
- 56% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
